Skip to main content
Jaakko Lappalainen, MD, Psychiatry, Philadelphia, PA

JaakkoLappalainenMD

Psychiatry Philadelphia, PA

Addiction

Staff Psychiatrist

Dr. Lappalainen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lappalainen's full profile

Already have an account?

  • Office

    3900 Woodland Ave
    Vamirecc
    Philadelphia, PA 19104
    Phone+1 203-676-1599

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Addiction Psychiatry, 2014 - 2015
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterResidency, Psychiatry, 2001
  • Other
    OtherClass of 1992

Certifications & Licensure

  • DE State Medical License
    DE State Medical License 2015 - 2025
  • PA State Medical License
    PA State Medical License 2013 - 2024
  • CT State Medical License
    CT State Medical License 1999 - 2015
  • American Board of Psychiatry and Neurology Psychiatry
  • American Board of Psychiatry and Neurology Addiction Psychiatry

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Marinus Announces Positive Preliminary Data from Children with CDKL5 Genetic Disorder
    Marinus Announces Positive Preliminary Data from Children with CDKL5 Genetic DisorderJanuary 23rd, 2017
  • Why This Seizure Drug Matters so Much for Marinus Pharma
    Why This Seizure Drug Matters so Much for Marinus PharmaJanuary 23rd, 2017
  • Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
    Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific ConferencesNovember 8th, 2023